A Randomized Non-comparative Open-label Phase 1b/2 Study of Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. "TRIFOUR Study"

Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) worldwide. The term triple negative means that tumor growth is not stimulated by the hormones estrogen and progesterone, nor by the HER2 protein, so unlike other types of BC, TNBC, which is an aggressive form of BC, does not have specific effective therapies available being the least common form of BC and the most difficult to treat.
Advanced or metastatic TNBC is treated with combinations of platinum-based chemotherapy with taxanes or gemcitabine with a 5-year survival rate of 12%. Recent studies have shown that TNBC expresses Interleukin 1 Receptor Accessory Protein (IL1RAP) at higher levels than other forms of BC.
Nadunolimab is a fully humanized monoclonal antibody that blocks the signals that occur within the cell produced by IL1RAP protein, thereby impairing the cancer cells' ability to secrete tumor stimulating substances, in turn reducing the tumor, inflammation and tumor progression. On the other hand, it is an antibody designed to activate the immune system to fight cancer cells.
This clinical trial is divided into two phases, phase Ib in which it is expected to include up to 18 patients and phase II in which it is expected to include 98 patients. The main purpose of phase Ib is to ensure that the combination of nadunolimab plus chemotherapy (gemcitabine plus carboplatin) is safe and determine the highest dose of nadunolimab that can be given safely without causing serious side effects. If the pre-specified objectives in this part are achieved, the trial will be expanded to a randomized phase II, to evaluate the efficacy of the combination of nadunolimab plus gemcitabine plus carboplatin, compared to a control group that will receive gemcitabine plus carboplatin only.

Start Date11 Jan 2022

Sponsor / Collaborator

Cantargia AB

[+1]

EUCTR2021-003402-46-ES / Unknown statusPhase 1/2

A randomized non-comparative open-label phase 1b/2 study of nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. TRIFOUR study”. - TRIFOUR

Start Date23 Sep 2021

Sponsor / Collaborator

Cantargia AB

EUCTR2021-001695-42-ES / Unknown statusPhase 1/2

A Phase 1/2 study of CAN04, a fully humanised monoclonal antibody against IL1RAP, in combination with different chemotherapy regimens in subjects with advanced solid tumours

Start Date22 Sep 2021

Sponsor / Collaborator

Cantargia AB

100 Clinical Results associated with Nadunolimab

100 Translational Medicine associated with Nadunolimab

100 Patents (Medical) associated with Nadunolimab

Literatures (Medical) associated with Nadunolimab

01 Mar 2023·Cancer immunology, immunotherapy : CII

Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy

Article

Author: Rydberg Millrud, Camilla ; von Wachenfeldt, Karin ; Deronic, Adnan ; Grönberg, Caitríona ; Liberg, David ; Forsberg, Göran ; Jaensson Gyllenbäck, Elin

IL-1α and IL-1β are both involved in several aspects of tumor biology, including tumor initiation, progression, metastasis, and not least in resistance to various therapies. IL-1α can function as an alarmin to signal cellular stress, and acts to induce downstream events, including production of IL-1β, to amplify the signal. Both IL-1α and IL-1β act through the same receptor complex, IL-1R1-IL1RAP, to mediate signal transduction. IL1RAP is expressed on tumor cells and in the tumor microenvironment by for example CAF, macrophages and endothelial cells. The anti-IL1RAP antibody nadunolimab (CAN04) inhibits both IL-1α and IL-1β signaling and induces ADCC of IL1RAP-expressing tumor cells. As both IL-1α and IL-1β mediate chemoresistance, the aim of this study was to explore the potential synergy between nadunolimab and chemotherapy. This was performed using the NSCLC PDX model LU2503 and the syngeneic MC38 model, in addition to in vitro cell line experiments. We show that chemotherapy induces expression and release of IL-1α from tumor cells and production of IL-1β-converting enzyme, ICE, in the tumor stroma. IL-1α is also demonstrated to act on stromal cells to further induce the secretion of IL-1β, an effect disrupted by nadunolimab. Nadunolimab, and its surrogate antibody, synergize with platinum-based as well as non-platinum-based chemotherapy to induce potent anti-tumor effects, while blockade of only IL-1β signaling by anti-IL-1β antibody does not achieve this effect. In conclusion, blockade of IL1RAP with nadunolimab reduces IL-1-induced chemoresistance of tumors.

01 Apr 2022·British journal of cancerQ1 · MEDICINE

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Q1 · MEDICINE

Article

Author: Eskens, Ferry ; Thorsson, Lars ; Steeghs, Neeltje ; Guren, Tormod Kyrre ; Jungels, Christiane ; Spanggaard, Iben ; Robbrecht, Debbie ; Fretland, Signe Ø ; Liberg, David ; Svedman, Christer ; Sorensen, Morten Mau ; Awada, Ahmad ; Aftimos, Philippe

BACKGROUND:

Interleukin-1 (IL-1) signalling is involved in various protumoural processes including proliferation, immune evasion, metastasis and chemoresistance. CAN04 is a first-in-class monoclonal antibody that binds IL-1 receptor accessory protein (IL1RAP), required for IL-1 signalling. In this first-in-human phase 1 study, we assessed safety, recommended phase 2 dose (RP2D), pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of CAN04 monotherapy.

METHODS:

Patients with advanced solid tumours known to express IL1RAP and refractory to standard treatments were enrolled in a dose-escalation study with 5 dose levels (1.0-10.0 mg/kg) of weekly CAN04.

RESULTS:

Twenty-two patients were enrolled. Most common adverse events were infusion-related reactions (41%), fatigue (32%), constipation (27%), diarrhoea (27%), decreased appetite (23%), nausea (23%) and vomiting (23%). One dose limiting toxicity was reported. No maximum tolerated dose was identified. Pharmacokinetics analyses indicate higher exposures and slower elimination with increasing doses. Decreases in serum IL-6 and CRP were observed in most patients. Twenty-one patients were evaluable for response, 43% had stable disease per immune-related response criteria with no partial/complete responses.

CONCLUSIONS:

The IL1RAP targeting antibody CAN04 can be safely administered to patients up to 10.0 mg/kg weekly, which was defined as the RP2D. Serum biomarkers supported target engagement and IL-1 pathway inhibition.

CLINICAL TRIAL REGISTRATION:

NCT03267316.

Frontiers in immunologyQ2 · MEDICINE

Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor

Q2 · MEDICINE

ArticleOA

Author: Fields, James K ; Sjöström, Kjell ; Klontz, Erik H ; Kihn, Kyle ; Deredge, Daniel ; Sundberg, Eric J ; Snyder, Greg A ; Beadenkopf, Robert ; Günther, Sebastian ; Birkedal, Gabriel S ; Liberg, David ; Forsberg, Göran

Interleukin-1 (IL-1) family cytokines are potent mediators of inflammation, acting to coordinate local and systemic immune responses to a wide range of stimuli. Aberrant signaling by IL-1 family cytokine members, however, is linked to myriad inflammatory syndromes, autoimmune conditions and cancers. As such, blocking the inflammatory signals inherent to IL-1 family signaling is an established and expanding therapeutic strategy. While several FDA-approved IL-1 inhibitors exist, including an Fc fusion protein, a neutralizing antibody, and an antagonist cytokine, none specifically targets the co-receptor IL-1 receptor accessory protein (IL-1RAcP). Most IL-1 family cytokines form productive signaling complexes by binding first to their cognate receptors – IL-1RI for IL-1α and IL-1β; ST2 for IL-33; and IL-36R for IL-36α, IL-36β and IL-36γ – after which they recruit the shared secondary receptor IL-1RAcP to form a ternary cytokine/receptor/co-receptor complex. Recently, IL-1RAcP was identified as a biomarker for both AML and CML. IL-1RAcP has also been implicated in tumor progression in solid tumors and an anti-IL1RAP antibody (nadunolimab, CAN04) is in phase II clinical studies in pancreatic cancer and non-small cell lung cancer (NCT03267316). As IL-1RAcP is common to all of the abovementioned IL-1 family cytokines, targeting this co-receptor raises the possibility of selective signaling inhibition for different IL-1 family cytokines. Indeed, previous studies of IL-1β and IL-33 signaling complexes have revealed that these cytokines employ distinct mechanisms of IL-1RAcP recruitment even though their overall cytokine/receptor/co-receptor complexes are structurally similar. Here, using functional, biophysical, and structural analyses, we show that antibodies specific for IL-1RAcP can differentially block signaling by IL-1 family cytokines depending on the distinct IL-1RAcP epitopes that they engage. Our results indicate that targeting a shared cytokine receptor is a viable therapeutic strategy for selective cytokine signaling inhibition.

News (Medical) associated with Nadunolimab

14 Jun 2024

·www.biospace.com

Cantargia Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10

LUND, SE / ACCESSWIRE / June 14, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; NasdaqStockholm:CANTA) today reported progress in the ongoing phase 1 clinical trial of the CAN10 antibody. Seven dose groups have now been concluded without any safety concerns. Furthermore, additional receptor occupancy studies confirm that CAN10 saturates its target molecule, IL1RAP, on immune cells from the study participants. The study follows timelines with the next dose group starting immediately, followed by the first group investigating multiple dosing, planned to start during Q3. "The CAN10 program has passed another important milestone, and the new data strengthen our confidence in the program. With its unique mechanism of action addressing the disease promoting activity of the IL-1 family, CAN10 has huge potential to treat a large number of autoimmune/inflammatory diseases. We look forward to the continued evaluation including upcoming studies in patients," said Göran Forsberg, CEO of Cantargia. CAN10 is one of two clinical projects in the Cantargia pipeline. The CAN10 antibody has been designed for treatment of autoimmune/inflammatory diseases and has "pipeline in a pill" potential with several possible target indications. The phase 1 clinical trial investigates increasing levels of CAN10 as single dose administration in healthy subjects followed by studies of multiple dosing in participants with mild to moderate psoriasis. The primary endpoint relates to safety. Details on the trial can be found at . The first seven dose groups in healthy volunteers have now concluded the treatment period. No safety concerns have been observed and the eighth dose group is about to start in accordance with the protocol. In addition, the important receptor occupancy study continues to follow predictions from preclinical studies and complete target saturation has now been documented on both monocytes and neutrophils. Biomarker samples taken during the study are being analyzed to document a dose dependent inhibition of IL-1 and IL-36 stimulated release of biomarkers from immune cells. Additional biomarker results based on the first seven dose groups are expected mid-2024. Dosing in participants with psoriasis are expected to start Q3 2024 ahead of phase 2 in 2025. This information is information that Cantargia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-06-14 11:05 CEST. About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia's oncology program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . About CAN10 The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. Inhibition of these signals can be of significant value in the treatment of several inflammatory or autoimmune diseases. The initial focus of CAN10 will be on two severe diseases: myocarditis and systemic sclerosis. In preclinical in vivo models of myocarditis, a CAN10 surrogate antibody significantly reduced the development of inflammation and fibrosis, and significantly counteracted the deterioration of the cardiac function. The CAN10 surrogate also inhibited disease development in models of systemic sclerosis, psoriasis, psoriatic arthritis, atherosclerosis and peritonitis. A clinical phase I study, investigating CAN10 in healthy volunteers and psoriasis patients, is ongoing. Up to 80 subjects may be included in the trial, the first clinical data set shows good safety. Additional data from the trial are expected continuously during 2024. Attachments Cantargia reports further progress in ongoing phase 1 clinical trial with CAN10 SOURCE: Cantargia View the original press release on accesswire.com

Phase 1ADC

01 Jun 2024

·www.biospace.com

Cantargia ASCO Presentation Highlights Positive Clinical Data on Nadunolimab Counteracting Neuropathy

LUND, SWEDEN / ACCESSWIRE / June 1, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today gave a presentation at the ASCO conference showing clinical data on nadunolimab counteracting the serious problem of chemotherapy induced neuropathy, an additional positive finding beyond its promising antitumor effects. The data focus on 73 pancreatic cancer patients receiving nadunolimab and chemotherapy. A key finding is higher dose levels of nadunolimab correlated to lower incidence of neuropathy. This protective effect is further supported by strong preclinical findings on neuropathy induced by two different types of chemotherapy. The new results can be accessed at Cantargia's webpage . "The ASCO presentation, highlighting these unique new data on nadunolimab, is an important opportunity for Cantargia to meet with the key stake holders in oncology and take the next step in the development of nadunolimab," said Göran Forsberg, CEO of Cantargia. The key data were published in a press release May 23. Major findings are: The incidence of neuropathy was notably lower than expected from chemotherapy treatment in the 73 first line pancreatic cancer patients treated with nadunolimab and gemcitabine/nab-paclitaxel. Only one grade 3 event was observed and a statistically significant (p=0.042) relationship between dose level and any grade neuropathy was observed. At 1 mg/kg nadunolimab, 60% of patients had any grade neuropathy with a median time to onset of 112 days. At 2.5 mg/kg or higher, only 36% had any grade neuropathy and median time to onset was not reached. The efficacy also shows signals of activity with median survival of 13.2 months and iPFS of 7.2 months, both longer than expected from historical control data for the chemotherapy alone(1). Studies in mouse models show that several aspects of chemotherapy induced neuropathy, such as sensitivity to mechanical pressure, temperature and decreased grip strength, all were prevented by concomitant treatment with the nadunolimab surrogate antibody. Combination studies were performed with either paclitaxel or vincristine and all results were statistically significant. Neuropathy is a serious medical condition and a side effect of several classes of chemotherapies. The main symptoms are weakness, pain and numbness in hands and feet. Neuropathy often leads to discontinuation of therapy in patients despite effective antitumor activity. The mechanisms behind chemotherapy induced neuropathy relate to damaged nerve cells and neuroinflammation, where the IL-1 pathway has been indicated as a key driver. The preclinical data were generated in collaboration with Hana Starobova and colleagues at University of Queensland, Australia. The results were presented by Prof. Eric van Cutsem, UZ Leuven Gashuisberg, Belgium at the ASCO Annual Meeting May 31st - June 4th, 2024, in Chicago, USA and the poster has been published on Cantargia's website . Reference 1) OS 8.5 mo, PFS 5.3 mo, (Von Hoff et al, N Engl J Med 2013); OS 9.2 mo, PFS 5.6 mo, (Wainberg et al, Lancet 2023) About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . About nadunolimab (CAN04) The antibody nadunolimab binds strongly to its target IL1RAP and functions by inducing ADCC and blocking IL-1alpha and IL-1beta signaling. Nadunolimab can thereby counteract the IL-1 system which contributes to the immune suppressive tumor microenvironment and development of resistance to chemotherapy. Nadunolimab is investigated in multiple clinical trials; the phase I/IIa trial CANFOUR, NCT03267316 , evaluates nadunolimab in combination with standard chemotherapies in patients with PDAC (gemcitabine/nab-paclitaxel) or NSCLC (platinum-based chemotherapies). Positive interim data show durable responses for the combination therapy in 73 PDAC patients, resulting in median iPFS of 7.2 months and median OS of 13.2 months. An even higher median OS of 14.2 months was observed in a subgroup of patients with high tumor levels of IL1RAP. Strong efficacy was also observed in 30 NSCLC patients with median PFS of 7.0 months and a response rate of 53%; even higher responses were observed in non-squamous NSCLC patients. Early efficacy data from the phase Ib/II trial TRIFOUR, NCT05181462 , also shows signs of promising efficacy in TNBC with a 60% response rate for nadunolimab combined with carboplatin/gemcitabine. Nadunolimab is also investigated with chemotherapy in the clinical trials CAPAFOUR, NCT04990037 , and CESTAFOUR, NCT05116891 , and with the checkpoint inhibitor pembrolizumab in the CIRIFOUR trial, NCT04452214. Attachments Cantargia ASCO presentation highlights positive clinical data on nadunolimab counteracting neuropathy CANFOUR PDAC Poster ASCO 2024 SOURCE: Cantargia View the original press release on accesswire.com

Clinical ResultImmunotherapy

23 May 2024

·www.biospace.com

Annual General Meeting in Cantargia AB (publ) - May 23, 2024

LUND, SWEDEN / ACCESSWIRE / May 23, 2024 / Cantargia's (STO:CANTA) Annual General Meeting on 23 May 2024 resolved in accordance with the following: That no dividend would be paid. To discharge the board members and the CEO from liability with respect to their management of the company for 2023. That the board shall consist of five members with no deputies. That the remuneration to the members of the board shall amount to SEK 1,675,000 in total, whereby SEK 595,000 shall be distributed to the chairman of the board and SEK 270,000 shall be distributed to each of the other board members. As remuneration for work performed on a committee, SEK 100,000 shall be distributed to the chairman of the audit committee and SEK 50,000 to each of the other members of the committee. SEK 50,000 shall be distributed to the chairman of the remuneration committee and SEK 25,000 to each of the other members of the committee. SEK 250,000 shall be distributed to the chairman of the drug development committee and SEK 50,000 to each of the other members of the committee. In addition, SEK 20,000 shall be distributed to each member residing outside the Nordic region for each physical board meeting (however, not more than six meetings) held in Sweden, attended by such member. That remuneration to the auditor shall be paid in accordance with approved invoices. To re-elect the board members Magnus Persson, Anders Martin-Löf, Flavia Borellini, Magnus Nilsson and Damian Marron and to re-elect Magnus Persson as the chairman of the board. To re-elect Öhrlings PricewaterhouseCoopers AB as auditor. To approve the remuneration report presented by the board of directors. To adopt guidelines for remuneration to senior executives, principally entailing that the company shall offer a competitive remuneration in order to be able to recruit and retain qualified personnel who are working to achieve the maximum level of shareholder and customer value. To adopt a long-term variable share-based incentive scheme for senior executives and key personnel within the company under which the participants commit to use distributed variable cash remuneration to acquire shares in the company on the stock market. To authorize the board to, with or without pre-emptive rights for shareholders, resolve on the issue of new shares, however not more than 10 per cent of the number of outstanding shares in the company as per the day of the annual general meeting. About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis. Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at . Attachments Annual General Meeting in Cantargia AB (publ) SOURCE: Cantargia View the original press release on accesswire.com

100 Deals associated with Nadunolimab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pancreatic Cancer	Phase 2	US	Cantargia AB	20 Feb 2024
Advanced Triple-Negative Breast Carcinoma	Phase 2	ES	Cantargia AB	11 Jan 2022
Advanced Malignant Solid Neoplasm	Phase 2	FR	Cantargia AB	22 Sep 2021
Advanced Malignant Solid Neoplasm	Phase 2	ES	Cantargia AB	22 Sep 2021
Biliary Tract Neoplasms	Phase 2	FR	Cantargia AB	22 Sep 2021
Biliary Tract Neoplasms	Phase 2	ES	Cantargia AB	22 Sep 2021
Colorectal Cancer	Phase 2	AT	Cantargia AB	19 Sep 2017
Colorectal Cancer	Phase 2	BE	Cantargia AB	19 Sep 2017
Colorectal Cancer	Phase 2	DK	Cantargia AB	19 Sep 2017
Colorectal Cancer	Phase 2	EE	Cantargia AB	19 Sep 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03267316 (CANFOUR, ASCO2024)	Phase 1/2	Pancreatic Cancer	73	Nadunolimab 1 mg/kg	qtbyqirjjp(ccksibzmrt) = qpdtzizdlw ozrvuasdor (acehduyjzr ) View more	Positive	24 May 2024
NCT03267316 (CANFOUR, ASCO2024)	Phase 1/2	Pancreatic Cancer	73	Nadunolimab 2.5 mg/kg	qtbyqirjjp(ccksibzmrt) = dqrbfrhcwa ozrvuasdor (acehduyjzr ) View more	Positive	24 May 2024
NCT05181462 (TRIFOUR, ESMO2023) Manual	Phase 1/2	Triple Negative Breast Cancer HER2 Negative \| ER Negative \| PR Negative	13	nadunolimab++gemcitabine 1000 mg/m2+carboplatin 2 mg/mL/min (Nadunolimab 1 mg/kg)	qegswmhhob(wafbbrwcmr) = krwxwaydea frzdmzciuz (bsrrjyaapi )	Positive	21 Oct 2023
NCT05181462 (TRIFOUR, ESMO2023) Manual	Phase 1/2		13	nadunolimab++gemcitabine 1000 mg/m2+carboplatin 2 mg/mL/min (Nadunolimab 2.5 mg/kg)	qegswmhhob(wafbbrwcmr) = tfpbryuqjx frzdmzciuz (bsrrjyaapi )	Positive	21 Oct 2023
CANFOUR (AACR2023)	Phase 1/2	Pancreatic Ductal Adenocarcinoma	73	Nadunolimab	ebkrnudmyn(uagtfsshjr) = lujqokgzvn hldecdfbyb (ujxmcnclei, 10.0 - 19.1) View more	-	04 Apr 2023
NCT03267316 (CANFOUR, ASCO2022) Manual	Phase 1/2	Pancreatic adenocarcinoma	76	gemcitabine+nab-paclitaxel+nadunolimab	ekcfzuqlpy(thkasiupfm) = Infusion-related reactions were reported in 29% (grade 3 in 3%). Peripheral sensory neuropathy was rare (only two grade 2 events). feypzwgspt (pndkgokrqa ) View more	Positive	02 Jun 2022
NCT03267316 (CANFOUR, ASCO2022) Manual	Phase 1/2	Non-Small Cell Lung Cancer	33	gemcitabine+Cisplatin+nadunolimab	kbjfdioohh(sxbrqigafy) = yhpyrlhddx pwpojfqqfu (rafxcxiyca ) View more	Positive	02 Jun 2022
NCT03267316 (CANFOUR, ASCO2022) Manual	Phase 1/2	Non-Small Cell Lung Cancer	33	gemcitabine+Cisplatin+nadunolimab	yufwdblunc(kaomkbxrkg) = xzckagrmbs wcomwqzoqw (atukaqlack )	Positive	02 Jun 2022
NCT04452214 (ASCO2022) Manual	Phase 1	Solid tumor	15	Pembrolizumab+Nadunolimab	ufaxatkesz(tfmtytxucm) = flcxbekjno xjftqyxymk (scjtrqvyyq ) View more	Positive	02 Jun 2022
NCT03267316 (CANFOUR, ESMO2021) Manual	Phase 1/2	Non-Small Cell Lung Cancer \| Pancreatic Cancer	58	Chemotherapy+CAN04 (PDAC)	mfiggsgbjz(ijekwmreok) = G1/2 IRRs were observed in 40% (G3 3%); 61% occurred at the priming dose. qigxkadswn (glojgkbsfd ) View more	Positive	16 Sep 2021
NCT03267316 (CANFOUR, ESMO2021) Manual	Phase 1/2	Non-Small Cell Lung Cancer \| Pancreatic Cancer	58	Chemotherapy+CAN04 (NSCLC)		Positive	16 Sep 2021
NCT03267316 (ASCO2021)	Phase 1/2	Pancreatic Cancer	36	CAN04 + nab-paclitaxel and gemcitabine	ekazrumlfj(bvjqckniag) = betqumfjig bjhyuibiro (rlzpnedhjt ) View more	-	28 May 2021
NCT03267316 (ASCO2019) Manual	Phase 2	Malignant Solid Neoplasm	22	CAN04	pqbebrxpbw(uwczecabhd) = whhrxnmqlo wgznxwivtu (uywvnegmra ) View more	Positive	02 Jun 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Nadunolimab

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation